Astrazeneca Ab

George Byron Mullen

Eifion D Phillips

Sheila Irene Hauck

Kenneth Gregory Hull

Oluyinka Morenike Green

Haihong Ni

James T Loch, Iii

Brian A Sherer

Neil James Hales

Michael Barry Gravestock

Gregory Steven Basarab

Fei Zhou

Michael Balestra

David Timms

Richard Schmiesing

Paul Robert Fleming

Pamela Hill

Alexander Louis Breeze

Brian Dangel

Greg Basarab

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. 

Antibacterial piperdine derivatives

Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. 

Pyrrol derivatives with antibacterial activity

Methods for the treatment of psychotic or intellectual impairment disorders with compounds of formula I, wherein A, R and Rare as defined in the specification.

Substituted amines of spirofuropyridines useful in therapy

A compound of formula I,wherein NRRis attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C&#x2013;Calkyl, or COR; Ris (CH)Ar, CHCH&#x2550;CHAr, or CHC&#x2261;CAr; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substitutents independently selected from: halogen, trifluoromethyl, or C&#x2013;Calkyl; Ris hydrogen, C&#x2013;Calkyl, C&#x2013;Calkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C&#x2013;Calkyl, C&#x2013;Calkenyl, C&#x2013;Calkynyl, OH; OC&#x2013;Calkyl, COR, &#x2014;CN, &#x2014;NO, &#x2014;NRR, or &#x2014;CF; R, Rand Rmay be hydrogen, C&#x2013;Calkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C&#x2013;Calkyl, C&#x2013;Calkenyl, C&#x2013;Calkynyl, OH; OC&#x2013;Calkyl, &#x2014;CN, &#x2014;NO, or &#x2014;CF; and enantiomers thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.

Arylkylamine spirofuropyridines useful in therapy

N-azabicyclo-amide derivatives

Growing community of inventors

Waltham, MA, United States of America

George Byron Mullen